SCHEMBL190703

SCHEMBL190703

NC(=O)OCc1cc(-c2ccc(OCc3ccccc3)cc2)ns1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 5/20 0.50
PARP10 Q53GL7 1/20 0.48
SMPD1 P17405 1/20 0.47
XDH P47989 1/20 0.47
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46
POLB P06746 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GSTP1 P09211 1/20 0.45
NR4A2 P43354 2/20 0.44
LTA4H P09960 1/20 0.44
NR4A1 P22736 1/20 0.44
NR4A3 Q92570 1/20 0.44
ENPP3 O14638 1/20 0.44
ENPP1 P22413 1/20 0.44
CHEK2 O96017 1/20 0.43
MGAM O43451 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL189840 0.79 RAB9A (0.59) MCL1PARP10SMPD1XDHMEN1
SCHEMBL222716 0.77 PARP10 (0.51) MCL1PARP10SMPD1XDHGSTP1
SCHEMBL6634107 0.77 PARP10 (0.68) PARP10RAB9ASMN1; SMN2NR4A2LTA4H
SCHEMBL190360 0.75 NR4A2 (0.51) MCL1SMPD1XDHMEN1NPC1
SCHEMBL189525 0.75 RAB9A (0.60) MCL1SMPD1MEN1NPC1POLB
SCHEMBL189580 0.74 RAB9A (0.52) MCL1PARP10SMPD1XDHMEN1
SCHEMBL27843564 0.74 NPC1 (0.58) MCL1SMPD1MEN1NPC1POLB
SCHEMBL16244407 0.73 SMPD1 (0.54) MCL1PARP10SMPD1XDHMEN1
SCHEMBL190096 0.72 FFAR1 (0.60) PARP10SMPD1NPC1RAB9ASMN1; SMN2
SCHEMBL28694024 0.71 PARP10 (0.64) PARP10RAB9ASMN1; SMN2NR4A2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290464-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-22 US claimed
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP claimed
US-20140350062-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO LTD (KR) 2014-11-27 US claimed
US-8841335-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-23 US claimed
US-8828992-B2 Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating Parkinson's disease using the same SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-09 US claimed
EP-2566475-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK Biopharmaceuticals Co., Ltd. (KR) 2013-03-13 EP claimed
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-02-21 US claimed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP claimed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US claimed
WO-2011139079-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-11-10 WO claimed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO claimed
US-9290464-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2016-03-22 US disclosed
EP-2401263-B1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO LTD (KR) 2016-02-17 EP disclosed
US-20140350062-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO LTD (KR) 2014-11-27 US disclosed
US-8841335-B2 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration SK BIOPHARMACEUTICALS CO., LTD. (KR) 2014-09-23 US disclosed
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2013-02-21 US disclosed
EP-2401263-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK Biopharmaceuticals Co., Ltd. (KR) 2012-01-04 EP disclosed
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK BIOPHARMACEUTICALS CO., LTD. 2011-12-08 US disclosed
WO-2011139079-A2 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION SK BIOPHARMACEUTICALS CO., LTD. (KR) 2011-11-10 WO disclosed
WO-2010098600-A2 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME SK HOLDINGS CO., LTD. (KR) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301150-A1 SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD FOR TREATING PARKINSON'S DISEASE USING THE SAME MAOB, MAOA, PARK7 MCL1 4046/4885PARP10 2440/4885SMPD1 1237/4885
US-20140350062-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION BAX, NLN, CASP3 MCL1 1474/4885PARP10 1834/4885SMPD1 313/4885
US-20130046001-A1 PHARMACEUTICAL COMPOSITION FOR INHIBITING APOPTOSIS OF NEURON OR NEURODEGENERATION BAX, NLN, CASP3 MCL1 1474/4885PARP10 1834/4885SMPD1 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.